SynthesisDiagnostic pathology2016
Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Synthesis in Diagnostic pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.Endocrine · 2020Pooled it
- The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.Medicine · 2018Pooled it
- Preoperative Detection of Dual TERT Promoter Mutations in Thyroid Cancer: A Case Series.Diagnostic cytopathology · 2026Article
- Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study.The Lancet. Oncology · 2025Article
- Role ofMolecular and clinical oncology · 2025Review
- Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas.Endocrine · 2024Article
- Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.The Journal of clinical endocrinology and metabolism · 2024Article
- An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2024Review
- Histopathology of telomerase reverse transcriptase promoter (Journal of clinical & translational endocrinology · 2024Article
- BRAFWorld journal of surgical oncology · 2023Review
- Molecular and clinical features of papillary thyroid cancer in adult patients with a non-classical phenotype.Frontiers in endocrinology · 2023Article
- Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients (Endocrinol Metab 2022;37:652-63, Heera Yang et al.).Endocrinology and metabolism (Seoul, Korea) · 2022Article
- Article
- Article
- Pyruvate carboxylase promotes thyroid cancer aggressiveness through fatty acid synthesis.BMC cancer · 2021Article
- Natural Phytochemicals Derived from Gymnosperms in the Prevention and Treatment of Cancers.International journal of molecular sciences · 2021Review
- Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.International journal of molecular sciences · 2021Review
- Value of Pyruvate Carboxylase in Thyroid Fine-Needle Aspiration Wash-Out Fluid for Predicting Papillary Thyroid Cancer Lymph Node Metastasis.Frontiers in oncology · 2021Article
- Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.Endocrine pathology · 2020Article
- Late-onset distant metastases confer poor prognosis in patients with well-differentiated thyroid cancer.Gland surgery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMutations in the TERT promoter, ALK rearrangement, and the BRAF V600E mutation are associated with aggressive clinicopathologic features in thyroid cancers. However, little is known about the impact of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of BRAF mutations.
methodsWe performed Sanger sequencing to detect BRAF V600E and TERT promoter mutations and both immunohistochemistry and fluorescence in situ hybridization to identify ALK rearrangement on 243 thyroid cancers.
resultsTERT promoter mutations were not present in 192 well-differentiated thyroid carcinomas (WDTC) without distant metastasis or in 9 medullary carcinomas. However, the mutations did occur in 40 % (12/30) of WDTC with distant metastasis, 29 % (2/7) of poorly differentiated carcinomas and 60 % (3/5) of anaplastic carcinomas. ALK rearrangement was not present in all thyroid cancers. The BRAF V600E mutation was more frequently found in WDTC without distant metastasis than in WDTC with distant metastasis (p = 0.007). In the cohort of WDTC with distant metastasis, patients with wild-type BRAF and TERT promoter had a significantly higher response rate after radioiodine therapy (p = 0.024), whereas the BRAF V600E mutation was significantly correlated with progressive disease (p = 0.025).
conclusionsThe TERT promoter mutation is an independent predictor for distant metastasis of WDTC, but ALK testing is not useful for clinical decision-making in Korean patients with a high prevalence of the BRAF V600E mutation. Radioiodine therapy for distant metastasis of WDTC is most effective in patients without BRAF V600E and TERT promoter mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.